What is the difference between AOD-9604 and IGF-2?

AOD-9604: AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. IGF-2: Binds IGF-1R and insulin receptor variant A; promotes anabolic signaling in muscle and fat; activates PI3K/Akt/mTOR pathway; different receptor binding profile than IGF-1

Is IGF-2 FDA approved?

IGF-2 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is IGF-2 administered in research settings?

In research settings, IGF-2 is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AOD-9604 vs IGF-2

Peptide Comparison

AOD-9604 vs IGF-2

Name: AOD-9604 vs IGF-2 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

AOD-9604

Advanced Obesity Drug 9604

Fat LossResearch Only

Half-life: 30–60 minutes

197 providers listed

Full AOD-9604 profile →

IGF-2

Insulin-like Growth Factor 2

PerformanceNot EvaluatedResearch Only

Half-life: ~10-20 minutes

No providers listed yet

Full IGF-2 profile →

Bottom line

IGF-2 carries stronger published evidence (Case series, 6 key studies) than AOD-9604 (Animal, 1); both are research compounds.

Quick Verdict

AOD-9604

Half-life

30–60 minutes

IGF-2

Half-life

~10-20 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	IGF-2
Less frequent dosing (longer half-life)	AOD-9604
Oral administration option	AOD-9604
More provider options (197 vs 0)	AOD-9604

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

AOD-9604

IGF-2

Mechanism Family

GH / IGF Axis

Half-life

30–60 minutes

~10-20 minutes

FDA Status

nomination withdrawn

not evaluated

Admin Routes

subcutaneous, oral

subcutaneous, intramuscular

Availability

Research Only

Providers

197 listed

None listed

Avail. Notes

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

Endogenous growth factor. No FDA-approved exogenous IGF-2 drug product. No NDA or IND for IGF-2 as primary active ingredient. Research use only.

Research Evidence

AOD-9604

Animal · 1 key study · dated evidence base — most recent 2001

IGF-2

Case series · 6 key studies · most recent 2026

Research Citations

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

IGF-2

Case series2026 · Endocrinol Diabetes Metab Case Rep

IGF-2-mediated hypoglycemia in a patient with a phyllodes tumor of the breast: a rare presentation of non-isl…

In vitro2026 · Atherosclerosis

Proteomics and ex vivo plaque culture identify the insulin-like growth factor axis as a potential regulator o…

In vitro2011 · Molecular Endocrinology

TGF-β inhibits muscle differentiation by blocking autocrine signaling pathways initiated by IGF-II

Animal2003 · Journal of Biological Chemistry

Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation

+2 more

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About IGF-2

Binds IGF-1R and insulin receptor variant A; promotes anabolic signaling in muscle and fat; activates PI3K/Akt/mTOR pathway; different receptor binding profile than IGF-1

Research Areas

muscle growthfat metabolismtissue developmentrecovery

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

IGF-2

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

AOD-9604

$9.00/mg

$7.71 – $11.85 range

45 vendors

View price index →Find providers →

IGF-2

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

AOD-9604

197 listed

Browse directory →

Providers offering

IGF-2

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs IGF-2 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/aod-9604/igf-2

https://peptidebase.io/peptides/compare/aod-9604/igf-2 Methodology License Download JSON Download CSV